Roche settles patent lawsuit against Biogen over Actemra biosimilar

Roche's lawsuit, filed in July, said the biosimilar would infringe several patents related to the manufacture and use of its biologic drug.

Sandra Levy

11/6/2023

Roche has settled a patent lawsuit against Biogen over its biosimilar version of Roche's rheumatoid arthritis drug Actemra, according to a filing on Monday in Massachusetts federal court, per a Reuters report.

Roche and its subsidiaries Genentech and Chugai Pharmaceutical (4519.T) jointly told the court without providing further details that they, Biogen and its manufacturer Bio-Thera (688177.SS) had agreed to settle the case, the report said.

Last month, the Food and Drug Administration approved Biogen's Tofidence, the first approved biosimilar to Actemra. Roche's lawsuit, filed in July, said the biosimilar would infringe several patents related to the manufacture and use of its biologic drug, per the report.

Related Topics